Flavia Rivellini

Avellino, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience.

Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience.

Journal: Hematological oncology

Published: February 13, 2024

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 09, 2023

AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.

AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.

Journal: Cancer

Published: July 19, 2022

Neuroimaging of leptomeningeal myelomatosis: a rare and severe entity.

Neuroimaging of leptomeningeal myelomatosis: a rare and severe entity.

Journal: Annals of hematology

Published: April 07, 2022

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.

Journal: Frontiers in oncology

Published: December 07, 2020

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.

Journal: HemaSphere

Published: May 13, 2020

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Journal: British journal of haematology

Published: September 21, 2016

Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.

Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.

Journal: British journal of haematology

Published: April 16, 2015

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.

Journal: BMJ supportive & palliative care

Published: May 23, 2014

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Journal: European journal of haematology

Published: February 23, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026